Taylor Andrew Lawrence

CFO Taylor Andrew Lawrence buys 2,000 shares of OBIO at $2.55; stock down -61.2% from 52-week high amid cluster buy activity

CFO Taylor Andrew Lawrence purchased 2,000 shares at $2.55 on 2025-08-25, adding to holdings that now total 482.8K shares. The transaction occurs as the stock trades -61.2% below its 52-week high of $6.70 and has declined -21.0% over the past 30 days. A cluster pattern is present: 3 other insiders also bought within the past 14 days. However, the company's fundamentals remain challenged—it posted a net loss of -$19.4M in the latest quarter and reported annual revenue growth of -4.4%, with the company unprofitable over its most recent full fiscal year. Lawrence's prior open-market buy at this ticker (2024-12-19) did not demonstrate well-timed execution (90d return -8.3%), which tempers the signal strength of the current purchase relative to broader price deterioration.

CFO Taylor Andrew Lawrence buys 1,000 shares of OBIO at $4.83; stock -51.9% from 52-week high amid -21.9% revenue decline.

Taylor Andrew Lawrence, the Chief Financial Officer, purchased 1,000 shares at $4.83 on 2024-12-19, increasing his holdings from 343,960 to 344,960 shares. The transaction occurs against a backdrop of significant operational headwinds: Orchestra BioMed reported a net loss of $-15.4M in its most recent fiscal year, with revenue declining 21.9% year-over-year and latest quarterly revenue of only $987.0K. The stock has fallen 51.9% from its 52-week high of $10.22 and traded at $4.92 at filing, representing a modest open-market purchase of $4.8K by the company's financial officer. While small insider purchases by CFOs can occasionally signal perceived value, the company's unprofitability, material revenue contraction, and severe price depreciation warrant careful examination of whether this transaction reflects conviction or routine portfolio activity.